If you have been reading about GRF(1-29) and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
According to a 2003 report by Human Rights Watch, an estimated 15 million children in debt bondage in India work in slavery-like conditions to pay off their family's debts. Slavoj Žižek asserts that new forms of contemporary slavery have been created in the post-Cold War era of global capitalism, including migrant workers deprived of basic civil rights on the Arabian Peninsula, the total control of workers in Asian sweatshops and the use of forced labor in the exploitation of natural resources in Central Africa.
The source of the fungal contamination in Fleming's experiment remained a speculation for several decades. Fleming suggested in 1945 that the fungal spores came through the window facing Praed Street. This story was regarded as a fact and was popularised in literature, starting with George Lacken's 1945 book The Story of Penicillin. But it was later disputed by his co-workers including Pryce, who testified much later that Fleming's laboratory window was kept shut all the time. Ronald Hare also agreed in 1970 that the window was most often locked because it was difficult to reach due to a large table with apparatuses placed in front of it. In 1966, La Touche told Hare that he had given Fleming thirteen specimens of fungi (ten from his lab) and only one from his lab was showing penicillin-like antibacterial activity. After this, a consensus developed that Fleming's mould had come from La Touche's lab, a floor below Fleming's, as spores which had drifted in through the open doors. Craddock developed severe infection of the nasal antrum (sinusitis) and had undergone surgery. Fleming made use of the surgical opening of the nasal passage and started injecting penicillin on 9 January 1929 but without any effect, probably because the infection was with H. influenzae, a bacterium unsusceptible to penicillin. Fleming gave some of his original penicillin samples to his colleague, surgeon Arthur Dickson Wright for clinical testing in 1928. Although Wright reportedly said that it "seemed to work satisfactorily," there are no records of its use.
== Medical uses == Tazarotene is most commonly used topically to treat acne vulgaris, psoriasis, and photoaging. Like other topical retinoids, such as tretinoin and adapalene, tazarotene can be used in a regimen with benzoyl peroxide and/or an oral antibiotic, such as clindamycin or dapsone, for the treatment of acne. This results in increased efficacy compared to tazarotene monotherapy. Combination therapy utilizing tazarotene alongside a mid- to high-potency corticosteroid is more effective in treating psoriasis compared to monotherapy of either drug. Tazarotene can also be used for the treatment of photodamaged skin. It can reduce the histological and clinical signs of photodamaged skin, such as fine lines, wrinkles, hyperpigmentation, and lentigo. The therapy is more effective when used with the daily application of sunscreen.
Sources: en.wikipedia.org
Congenital myopathy is a very broad term for any muscle disorder present at birth. This defect primarily affects skeletal muscle fibres and causes muscular weakness and/or hypotonia. Congenital myopathies account for one of the top neuromuscular disorders in the world today, comprising approximately 6 in 100,000 live births every year. As a whole, congenital myopathies can be broadly classified as follows:
On Thursday, February 1, 1866, Mary Baker Eddy, then known as Mary Patterson, fell on the ice in Lynn, Massachusetts. She had been on the way to a Good Templars meeting, an organization supporting the temperance movement, with friends from the organization. After her fall, the Lynn Reporter wrote that she was "in an insensible condition" and had internal injuries, and the notes of Dr. Alvin M. Cushing, a homeopathic doctor, who was called to the scene, state that he found Eddy "partially unconscious, semi-hysterical and complaining by word and action of severe pain in the back of her head and neck." She was taken to the nearest house, that of Samuel M. Bubier the future mayor of Lynn, and spent the night there. Cushing attended to her multiple times that day and during the night, which Gill writes "indicates that he considered the accident serious," and he gave orders that homeopathic medicine be continually given her at intervals of every half hour when she was awake while he was not present. Cushing later told Sibyl Wilbur that Eddy "was taken up unconscious and remained unconscious during the night" and that he thought she was "suffering from a concussion, and possible spinal dislocation." The next morning Eddy asked to be taken to her home in Swampscott, which Cushing arranged for against his own professional advice. In order to dull the pain of moving, Cushing gave Eddy "one-eighth of a grain of morphine" (a common painkiller at the time) according to his notes from the period.
=== Agonists === Non-selective Galanin Galanin 1-15 fragment Galanin-like peptide - agonist at GAL1 and GAL2 but not GAL3 Galmic Galnon NAX 5055 D-Gal(7-Ahp)-B2 GAL1 selective M617 GAL1/2 selective M1154 - has no GalR3 interaction GAL2 selective Galanin 2-11 amide - also called AR-M 1896, anticonvulsant in mice, CAS# 367518–31–8 M1145 - selective compared to both GalR1 and GalR3 M1153 - selective compared to both GalR1 and GalR3 CYM 2503 (positive allosteric modulator)
Pulse chase assays are an alternative method to cycloheximide chase assays and involve the radioactive labeling of newly translated proteins followed by a similar "chase" period. While this method is informative and provides the benefit of observing nascent protein abundance, the radioactive material it requires is expensive with a shorter shelf-life and demands more caution to use than cycloheximide. Disadvantages Some disadvantages to conducting cycloheximide chase assays include the toxic nature of cycloheximide. When used at high concentrations over a long period of time, cycloheximide will damage the DNA within the cell and impair critical cellular function. For this reason, cycloheximide chases do not typically last for more than 12 hours. This presents a limitation if the turnover of a particularly stable protein is being studied. Additionally, cycloheximide chases only offer the ability to look at steady state proteins levels as opposed to newly translated protein levels such as with pulse chase. Therefore, only protein degradation and not protein maturation is able to be observed.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.